NCT06022055 Multimodal Study of the Human Brain Epilepsy Tissue
| NCT ID | NCT06022055 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Focal Drug-resistant Epilepsy |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-02-29 |
| Primary Completion | 2030-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2024-02-29 with a primary completion date of 2030-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The TIPI2 study is a blood and tissue collection protocol to create an annotated biorepository to support research in drug-resistant epilepsy. The aim of the study will be to identify new pathophysiological pathways. For this purpose, the investigators will investigate with a multimodal approach blood and brain samples from patients undergoing a surgery for focal drug-resistant epilepsy. The adult patients will be enrolled either during the pre-surgical evaluation or right before the surgery.
Eligibility Criteria
Inclusion Criteria: * 18 yo or above * patients with a focal drug-resistant epilepsy * patients hospitalized for a pre-surgical evaluation or for an epilepsy surgery * consent obtained from the patient, or legally authorized representative * affiliated to a social security system Exclusion Criteria: * None
Contact & Investigator
Vincent M. Navarro, MD, PHD
PRINCIPAL INVESTIGATOR
APHP
Frequently Asked Questions
Who can join the NCT06022055 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Focal Drug-resistant Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06022055 currently recruiting?
Yes, NCT06022055 is actively recruiting participants. Contact the research team at Vincent.navarro@aphp.fr for enrollment information.
Where is the NCT06022055 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT06022055 clinical trial?
NCT06022055 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Vincent M. Navarro, MD, PHD at APHP. The trial plans to enroll 150 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.